Case Control Study
Copyright ©The Author(s) 2022.
World J Hepatol. Jun 27, 2022; 14(6): 1142-1149
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1142
Table 1 General characteristics of cases and controls
Characteristics
Cases, n = 39
Controls, n = 78
Age, mean ± SD55.23 ± 13.5155.32 ± 13.65
Sex, males (%)26 (66.7)52 (66.7)
Race, n (%)
Caucasian31 (79.5)45 (57.7)
African American3 (7.7)11 (14.1)
Hispanic3 (7.7)14 (17.9)
Asian0 (0.0)2 (2.6)
Other/unknown2 (5.1)6 (7.7)
Presence of
Diabetes, n (%)17 (43.6)15 (19.2)
Hypertension, n (%)23 (59)30 (38.5)
Obesity, n (%)14 (35.9)28 (35.9)
Congestive heart failure, n (%)3 (7.7)6 (7.7)
Chronic kidney disease or hemodialysis, n (%)14 (35.9)8 (10.3)
Table 2 Characteristics of cases pertinent to liver transplantation
Characteristics
n
%
Additional renal transplantation
Yes615.4
No3384.6
Duration of liver transplantation
< 1 yr37.7
1 to < 5 yr1333.3
5 to 10 yr1230.8
> 10 yr 1128.2
Etiology of end-stage liver disease prior to liver transplantation
Alcohol use717.9
Chronic hepatitis C infection820.5
Nonalcoholic fatty liver disease512.8
Primary sclerosing cholangitis410.3
Other1538.5
Current status of liver transplant
Working3384.6
Failed/cirrhotic 615.4
Table 3 Death due to coronavirus disease 2019
Liver transplant recipient
Death due to COVID-19
Total
Odds ratio with 95% confidence interval
Two-sided P value
Yes
No
Yes237392.04 (0.14–29.17)0.6
No27678
Total 4113117
Table 4 Hospitalization due to coronavirus disease 2019
Liver transplant recipient
Hospitalization due to COVID–19
Total
Odds ratio with 95% confidence interval
Two-sided P value
Yes
No
Yes1227391.38 (0.59–3.24)0.46
No195978
Total3186117